Workshop: Stimulant Use Disorder Treatment: Updates from the ASAM/AAAP National Practice Guideline-Stimulant Use Disorder Treatment: Updates from the ASAM/AAAP National Practice Guideline

Video Transcription

Video Summary

The workshop centered on the newly published AAAP-ASAM clinical practice guideline for stimulant use disorder, emphasizing a comprehensive and holistic clinical management approach. The guidelines cover screening, diagnosis, behavioral and pharmacotherapy treatments, and specific populations like those with co-occurring disorders, adolescents, pregnant women, LGBTQ+ individuals, and those involved in the criminal justice system or experiencing homelessness. The utility of contingency management, a behavioral model rewarding patients for abstinence, is strongly highlighted as effective. Cognitive behavioral therapy (CBT), community reinforcement approaches, and adaptations within the matrix model are also emphasized. The workshop explored off-label pharmacotherapies for stimulant use disorders, where bupropion, mirtazapine, naltrexone-bupropion, topiramate, and methylphenidate were noted for methamphetamine use, while modafinil, topiramate, mixed amphetamine salts with topiramate, and bupropion were mentioned for cocaine use. The evidence for these pharmacotherapies is described as weak to moderate. The significant focus was placed on the necessity to monitor and manage risks when prescribing off-label controlled medications, stressing that only trained specialists should undertake such treatments. Special considerations are discussed, such as implementing integrated treatment plans for those with stimulant use disorder and co-occurring psychiatric disorders and promoting harm reduction strategies. The seminar concluded with a case discussion, emphasizing the complexity and variability in managing stimulant use disorder, highlighting individualized patient care and evidence-based strategies.

Keywords

AAAP-ASAM guideline

stimulant use disorder

Dr. Larissa Mooney

Dr. Brian Hurley

Dr. Severino

screening and assessment

contingency management

Cognitive Behavioral Therapy

Matrix Model

pharmacotherapy

co-occurring disorders

harm reduction

patient engagement

treatment adherence

AAAP-ASAM guidelines

comprehensive management

behavioral treatments

off-label pharmacotherapies

methamphetamine treatment

cocaine treatment

individualized care

	The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.		400 Massasoit Avenue Suite 108 East Providence, RI 02914 cmecpd@aaap.org Privacy	About Advocacy Membership Fellowship Education and Resources Training Events